There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on RxSight (RXST – Research Report), TransMedics Group (TMDX – Research Report) and Apellis Pharmaceuticals (APLS – Research Report) with bullish sentiments.
RxSight (RXST)
J.P. Morgan analyst Robbie Marcus maintained a Buy rating on RxSight yesterday and set a price target of $40.00. The company’s shares closed last Monday at $39.02, close to its 52-week high of $40.60.
According to TipRanks.com, Marcus is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for RxSight with a $37.75 average price target, which is a -4.3% downside from current levels. In a report issued on December 4, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $36.00 price target.
See today’s best-performing stocks on TipRanks >>
TransMedics Group (TMDX)
In a report released yesterday, Allen Gong from J.P. Morgan maintained a Buy rating on TransMedics Group, with a price target of $87.00. The company’s shares closed last Monday at $76.87.
According to TipRanks.com, Gong is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for TransMedics Group with a $86.80 average price target.
Apellis Pharmaceuticals (APLS)
J.P. Morgan analyst Anupam Rama maintained a Buy rating on Apellis Pharmaceuticals on December 15 and set a price target of $66.00. The company’s shares closed last Monday at $55.98.
According to TipRanks.com, Rama is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Apellis Pharmaceuticals with a $67.31 average price target, a 28.5% upside from current levels. In a report issued on December 4, Bank of America Securities also upgraded the stock to Buy with a $85.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RXST:
- RxSight price target raised by $7 at BTIG, here’s why
- RxSight price target raised to $43 from $36 at BTIG
- Microsoft initiated, Hertz downgraded: Wall Street’s top analyst calls
- Wells Fargo upgrades RxSight to Overweight, raises price target to $42
- Wells Fargo gets more bullish on RxSight, upgrades shares
